endocrinology
Edmonton Obesity Staging System (EOSS)
5-stage clinical staging system for obesity that incorporates comorbidities, functional limitations, and wellbeing — beyond BMI alone. Guides treatment intensity. Stage 0 = no complications; Stage 4 = end-stage complications.
References
- Sharma AM, Kushner RF. A proposed clinical staging system for obesity. Int J Obes. 2009;33(3):289–295.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Protamine Sulphate (Heparin Reversal) · Heparin Reversal / Cardiac Surgery
- Semaglutide · GLP-1 Receptor Agonist
- Liraglutide · GLP-1 Receptor Agonist
- Tirzepatide · Dual GIP/GLP-1 Receptor Agonist — Type 2 Diabetes / Obesity
- Naltrexone with bupropion · Anti-obesity (combination)
- Levonorgestrel Intrauterine System · Progestogen-Only Intrauterine Device
Pathways
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.